Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Eli Lilly's new serotonin norepinephrine reuptake inhibitors (SNRI), duloxetine, will be the most promising drug to be launched between 2001-2011 because it posses a mechanism of action similar to that of venlafaxine, a popular SNRI already on the market.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"Although both Wyeth's venlafaxine and Lilly's duloxetine will share approximately 20% of the depression market in 2011, duloxetine will be favored over venlafaxine because it is not as likely as venlafaxine to cause high blood pressure," said Anathea Waitekus, analyst at Decision Resources. "Duloxetine's favorable safety profile will be especially appealing to general practitioners and primary care physicians, who treat the majority of depression sufferers worldwide."

Disease Background-Depression

In 2001, in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), approximately 86 million people suffered from one or more unipolar depressive disorders (i.e., major depression, dysthymia, or another depressive disorder such as minor depression, brief recurrent depression, or subthreshold depression). A low diagnosis rate, patient noncompliance, and lack of development of drugs with improved efficacy continue to be challenges in depression treatment.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Depression is a Psychiatric Disorders report.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X96525776

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

Study Finds Keys to HMO Sustainability and Market Exit

View Now